

FUTURE ONCOLOGY

TECHNOLOGY, PRODUCTS, MARKETS AND SERVICE OPPORTUNITIES

A NEW MEDICINE PUBLICATION

VOLUME 3, NUMBER 1-12 INDEX

MAY 1998

TABLE OF CONTENTS

STATE-OF-THE-ART IN THE MANAGEMENT OF CANCER

OVARIAN CANCER — PART III	
CURRENT TREATMENT APPROACHES	
CYTOREDUCTIVE SURGERY	545
Second Look Surgery	546
Prophylactic Oophorectomy	547
RADIATION THERAPY	548
CHEMOTHERAPY	548
Primary Disease	549
Single-agent chemotherapy	549
Combination chemotherapy	549
Drug Resistance	551
Recurrent/Refractory Disease	551
High-Dose (Density) Chemotherapy with Autologous Bone Marrow and/or Stem Cell Transplants	557
Drug Administration Routes	561

OVARIAN CANCER — PART IV

NOVEL THERAPEUTIC APPROACHES IN DEVELOPMENT

ANALOGS, DERIVATIVES AND FORMULATIONS OF AGENTS APPROVED FOR THE TREATMENT OF OVARIAN AND OTHER CANCERS	570
Anthracyclines	570
Antra Pharmaceuticals	570
Platinum Analogs	571
Oxaliplatin	571
Taxanes	571
Paclitaxel	571
Docetaxel	581
Topoisomerase I Inhibitors	581
GW211	581
Gemcitabine	581
DRUG RESISTANCE	581
Methionine	581
AntiCancer	581
Molecular Markers	582
Resistance to Platinum-based/Alkylating Agents	582
Intracellular glutathione	583
Metallothioneins	583
Resistance to Taxanes	583
SDZ PSC 833	583
Chemoprotection	584
Genetix Pharmaceuticals	584

<i>Ingenex</i>	584
IMMUNOTHERAPY/VACCINES	584
AltaRex	584
AVAX Technologies	585
Biomira	585
Corixa	586
Trilex Pharmaceuticals	586
Other	586
SMALL MOLECULE DRUGS	586
CDR Therapeutics	586
Sugen	587
RADIOISOTOPES/RADIOIMMUNOCONJUGATES	587
Cancer Therapeutics	587
Immunomedics	588
NeoRx	588
University of Alabama	588
University of Chicago	589
PHOTODYNAMIC THERAPY	589
INHIBITION OF METASTASIS	589
Anika Therapeutics	589
MOLECULAR APPROACHES TO MANAGEMENT OF OVARIAN CANCER	589
BRCA1/BRCA2	590
p53	590
ras	590
Cortecs International	590
Her-2/neu (erbB-2)	590
Anti-erbB-2 sFv (Ad21)	590
Epidermal Growth Factor Receptor (EGFr)	590
HEAD AND NECK CANCER — PART I	
EPIDEMIOLOGY, ETIOLOGY AND MOLECULAR MARKERS	
EPIDEMIOLOGY	606
International Epidemiology	606
USA Epidemiology	606
ETIOLOGY AND RISK FACTORS	607
Oral Cancer	608
Nasopharyngeal Cancer	610
MOLECULAR MARKERS	610
Oncogenes and Tumor Suppressor Genes	610
Growth Factors	611
Matrix Metalloproteinases	612
Other Molecular Factors	613
MOLECULAR EPIDEMIOLOGY	613

HEAD AND NECK CANCER — PART II

DIAGNOSIS, STAGING, PROGNOSIS, AND TREATMENT

DIAGNOSIS, SCREENING AND STAGING	626
Panendoscopy	626
Non-invasive Imaging	627
In vitro Tests	627
Human papillomavirus (HPV)	627
Epstein-Barr virus	628
Telomerase	628
Cytology	629
Biological Staging	629
PROGNOSIS	629
p53	629
Growth Factors	631
Cyclin D1	631
Eukaryotic Initiation Factor 4E	631
HPV Infection	631
Multiple Markers	631
TREATMENT OPTIONS BY SITE OF CANCER	632
Oral Cavity and Oropharynx	633
Nasopharynx and Hypopharynx	633
Second Primary Tumors	633
MULTIMODALITY THERAPY	633

HEAD AND NECK CANCER — PART III

NOVEL THERAPEUTIC AND CHEMOPREVENTIVE APPROACHES IN DEVELOPMENT

RADIATION THERAPY	646
RADIOSENSITIZATION/ENHANCEMENT	646
Pharmacocyclics	647
Enzon	647
Vion Pharmaceuticals	648
PHOTODYNAMIC THERAPY	648
QLT PhotoTherapeutics	648
Scotia	648
COMMERCIALLY AVAILABLE AGENTS IN CLINICAL TRIALS IN HNSCC	650
Gemcitabine	650
Vinorelbine	650
Taxanes	650
NOVEL CHEMOTHERAPEUTICS	650
Thymidylate Synthase Inhibitors	650
Retinoids	650
ALRT1550	650
GENE THERAPY	651

p53	651	Scintigraphy	683	UPDATE OF PROSTATE CANCER — PART I	
<i>Introgen Therapeutics</i>	651	<i>In Vitro</i> Tests	683	EPIDEMIOLOGY	
<i>Schering-Plough Research Institute</i>	651	TUMOR STAGING	683	USA Epidemiology	731
p16	651	PROGNOSIS	684		
Suicide Genes	651			CANCER OF THE CENTRAL NERVOUS SYSTEM — PART III	
Onyx-015	654			NOVEL THERAPEUTIC APPROACHES	
Human Papillomavirus (HPV)	654			NOVEL CHEMOTHERAPEUTICS	731
GROWTH FACTORS/CYTOKINES	654	CANCER OF THE CENTRAL NERVOUS SYSTEM — PART II		9-aminocamptothecin (9-AC)	731
Epidermal Growth Factor (EGF) Receptor Inhibitors	654	CURRENT THERAPEUTIC APPROACHES		Alanosine	731
<i>Quinazolines</i>	654	SURGERY	702	Diaziquone	733
<i>MDX-447</i>	655	Conventional Surgery	702	Dibromodulcitol (DBD)	733
<i>MAb ICR62</i>	655	Stereotaxic Radiosurgery	702	Fluorodeoxyuridine (FdUrd)	734
Interferon as Adjuvant Therapy	655	RADIOTHERAPY	703	Hypericin	734
Tumor Necrosis Factor α (TNF- α)	655	Conventional Radiation Therapy	703	Mivobulin Isethionate	734
IMMUNOTHERAPY/VACCINES	655	Interstitial Radiation or Brachytherapy	703	O(6)-benzylguanine	734
Cel-Sci	655	<i>International Isotopes</i>	705	Phenylacetate	735
GeneMedicine	656	Boron Neutron Capture Therapy (BNCT)	706	Phenylbutyrate	735
University of Pittsburgh	656	<i>Boron Biologicals</i>	706	Rebeccamycin Analog	735
MANAGEMENT OF TREATMENT-RELATED COMPLICATIONS	656	Radiosensitizers	707	Suramin	735
Amifostene	656	<i>Cisplatin or carboplatin</i>	707	Temozolomide	736
Lisofylline	656	<i>Etanidazole</i>	707	UCN-01	736
Oralase	656	<i>Gadolinium texaphyrin (Gd-TeX)</i>	707	RECEPTOR TARGETING STRATEGIES	737
DRUG DELIVERY	657	<i>Halogenated pyrimidine analogs</i>	707	CEP751	737
Genetronics	657	<i>Neu-Sensamide</i>	709	IL4 (38-37)-PE38KDEL	737
CHEMOPREVENTION	657	<i>Tirapazamine</i>	709	IL13-PE38QQR	738
		HYPERTHERMIA	709	SU101	738
CANCER OF THE CENTRAL NERVOUS SYSTEM — PART I		PHOTODYNAMIC THERAPY	709	THERAPY ENHANCEMENT	738
EPIDEMIOLOGY, ETIOLOGY, DIAGNOSIS AND PROGNOSIS		<i>Pacific Pharmaceuticals</i>	709	Radiosensitization	738
WORLDWIDE EPIDEMIOLOGY OF PRIMARY CNS TUMORS	670	CHEMOTHERAPY	710	<i>RSR-13</i>	738
USA Epidemiology	670	Approved Drugs for CNS Cancer Indications	710	Chemosensitization	738
<i>Gender</i>	670	<i>Carmustine and lomustine</i>	710	<i>Artificial oxygen carriers</i>	738
<i>Race</i>	670	<i>Gliadel</i>	710	Chemoprotection	739
<i>Age</i>	670	Commercial Drugs in Clinical Trials for CNS Cancer Indications	712	<i>Dexrazoxane</i>	739
EPIDEMIOLOGY OF SECONDARY CNS TUMORS	670	Chemotherapy Delivery Options	712	NOVEL APPROACHES TO PREVENT/TREAT METASTASES	739
EPIDEMIOLOGY OF METASTATIC CNS CANCER	672	<i>Intra-arterial chemotherapy</i>	712	Matrix Metalloproteinase (MMP) Inhibitors	739
Neoplastic Meningitis	672	<i>Intrathecal chemotherapy</i>	712	<i>Bryostatin-1</i>	739
ETIOLOGY OF PRIMARY TUMORS OF THE CNS	673	<i>DepoCyt</i>	717	<i>Marimastat</i>	745
Hereditary/Familial Factors	673	HEMATOPOIETIC SUPPORT/BONE MARROW TRANSPLANTATION	718	Inhibition of Angiogenesis	746
Environmental Factors	674	CURRENT TREATMENT BY TUMOR TYPE	723	<i>Carboxamide triazole (CAI)</i>	746
Other Factors	674	Primary Malignant CNS Cancer	723	<i>MAb 81C6</i>	746
MOLECULAR GENETICS AND MOLECULAR BIOLOGY OF PRIMARY BRAIN TUMORS	675	Pediatric Tumors	723	<i>Thalidomide</i>	746
Gene Factors	675	Metastatic Brain Tumors and Cancer Metastasized to the Brain	724	<i>TNP-470</i>	746
<i>Chromosomal/gene abnormalities</i>	675	MANAGEMENT OF TREATMENT-RELATED AND OTHER COMPLICATIONS	724	<i>Vascular endothelial growth factor (VEGF)</i>	746
<i>Gene amplification</i>	680	Hearing Loss	724	Selective Targeting of Tumor Vasculature	747
Growth Factors	681	Peritumoral Brain Edema	724	Exploiting Other Mechanisms	747
DIAGNOSIS	681	<i>Shunts</i>	725	<i>Brain-enriched hyaluronan-binding protein (BEHAB)</i>	747
Neuroimaging	682	<i>Steroids</i>	725	<i>Glioma-specific Chloride Channel</i>	747
Stereotactic Techniques for Tissue Sampling	683	<i>Human corticotropin-releasing factor (hCRF)</i>	725	IMMUNOTHERAPY/VACCINES	747
		Seizures	725	Antigen-specific Cellular Immunotherapy	747

Activated Cytotoxic T Cells	747
Genetically-modified Tumor Cells	748
<i>Granulocyte-macrophage colony-stimulating factor (GM-CSF)</i>	748
<i>Immune Response</i>	748
Anti-hCG Vaccines	748
Administration of Growth Factors/Cytokines	748
"SUICIDE" GENE THERAPY	749
Adenoviral Vector-mediated Transfer	749
<i>IntroGene</i>	749
<i>University of Pennsylvania</i>	749
Parvoviral Vector-mediated Transfer	749
<i>Avigen</i>	749
Retroviral Vector-mediated Transfer	750
<i>Chiron</i>	750
<i>Genetic Therapy/Novartis</i>	750
MONOCLONAL ANTIBODIES	750
<i>Lexigen Pharmaceuticals</i>	750
<i>Techniclone</i>	751
NOVEL POTENTIAL TREATMENTS DRIVEN BY NEW GENE DISCOVERIES	751
DELIVERY OF THERAPEUTICS TO THE BRAIN	752
Electroporation for Delivery of Genes	752
Crossing the Blood-Brain Barrier (BBB)	752
<i>Cereport</i>	752
<i>SP2000 Biotransport</i>	752

**PROSTATE CANCER — PART II
DIAGNOSIS, STAGING,
PROGNOSIS, SCREENING,
AND NOVEL MOLECULAR
MARKERS**

DIAGNOSTIC AND SCREENING TESTS	762
Prostate-specific Antigen (PSA)	762
Prostate Acid Phosphatase (PAP)	764
ProstaScint	764
Angiogenesis	764
Cytokine Overexpression	765
NOVEL MOLECULAR MARKERS	765
Markers Associated with Familial/Hereditary Prostate Cancer	766
<i>Androgen receptor</i>	766
<i>BRCA1 or BRCA2</i>	766
<i>Hereditary prostate cancer 1 (HPCA1)</i>	766
Other Markers	768
<i>Insulin-like growth factor-I (IGF-I)</i>	768
<i>Nuclear matrix proteins (NMPs)</i>	768
<i>P53</i>	769
<i>Prostate specific membrane antigen (PSMA)</i>	769
<i>Prostate stem cell antigen (PSCA)</i>	769

MEETING COVERAGE

ASCUS PATIENT MANAGEMENT IN CERVICAL CANCER SCREENING	
FROM THE 45TH ANNUAL CLINICAL MEETING OF THE AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS	
LAS VEGAS, NV, APRIL 28-30, 1997	
SCREENING AND DIAGNOSIS OF CERVICAL CANCER	562
ROLE OF HUMAN PAPILLOMAVIRUS IN CERVICAL CANCER	562
Digene's Hybrid Capture HPV DNA Assay	564
DIAGNOSTIC TRIAGE USING HPV SCREENING	564

NEW DEVELOPMENTS IN THE TREATMENT OF GYNECOLOGIC CANCERS

FROM THE 21ST CONGRESS OF THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY	
VIENNA, AUSTRIA, NOVEMBER 1-5, 1996	
INVASIVE CERVICAL CANCER	565
Metastatic Cervical Cancer	565
<i>HIV-related invasive cervical cancer</i>	565
Combination Regimens in Invasive Cervical Cancer	565
<i>BEMP regimen</i>	565

DEMYSTIFYING THE ROLE OF CYTOKINES IN TUMOR IMMUNOBIOLOGY

REPORT FROM THE 88TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH APRIL 12-16, 1997 SAN DIEGO, CA	
MECHANISMS OF GENE REGULATION BY TUMOR NECROSIS FACTOR (TNF)	601
FLT 3 LIGAND (FLT-3L)	601
IL-6 RECEPTOR SUPER-ANTAGONISTS (SANTS): NEW TOOLS FOR MULTIPLE MYELOMA	602
CYTOKINES THAT PREVENT OR PROMOTE TUMOR CELL DEATH	602
EBV-associated Lymphoma	602
EBV-associated AIDS Primary CNS Lymphomas (AIDS-PCNSL)	603
Natural Killer (NK) Cell Leukemias	603

NEW APPROACHES IN THE TREATMENT OF GASTROINTESTINAL CANCERS

FROM THE 33RD ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	
DENVER, CO, MAY 17-20, 1997	
GASTRIC CANCER	620
Monotherapy	620
<i>Docetaxel</i>	620
<i>Paclitaxel</i>	620

Combination Therapies	620
HEPATOCELLULAR CARCINOMA	621
Multimodality Therapy	621
<i>Liver transplantation combined with neoadjuvant and adjuvant chemotherapy</i>	621
Intra-arterial Lipiodol-iodine 131	621
PANCREATIC CANCER	621
PNU-214565	621
COLORECTAL CANCER	622
Monotherapy	622
<i>AG-337</i>	622
<i>Raltitrexed</i>	622
<i>Irinotecan</i>	622
<i>Capecitabine</i>	622
Combination Regimens	623
5-FU Administration Options	623
Multimodality Therapy	623
<i>Chemoradiation</i>	623
CARCINOID SYNDROME	623
Octreotide Acetate LAR	623

NEW APPROACHES FOR THE TREATMENT OF HEAD AND NECK CANCER

FROM THE 33RD ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	
DENVER, CO, MAY 17-20, 1997	
MULTIMODALITY THERAPY	641
Taxanes	641
<i>Docetaxel</i>	641
Paclitaxel	641
Thymidylate Synthase Inhibitors	642
<i>AG337</i>	642
RADIOSENSITIZATION	642
Tirapazamine	642
CHEMOTHERAPY	642
Vinorelbine	642
GENE THERAPY	642
Adp53	642
EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONIST	643
C225	643
INTERFERON-α	643
Induction	643
Biochemoprevention	643

OPPORTUNISTIC INFECTIONS IN IMMUNOCOMPROMISED PATIENTS

FROM THE 37TH INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (ICAAC), TORONTO, ONTARIO, CANADA, SEPTEMBER 28-OCTOBER 1, 1997	
BACTERIAL INFECTIONS	657
Risk Factors For Gram-Positive Infections	658
Capnocytophaga Bacteremia	658
The Growing Problem of Vancomycin-Resistant Enterococci	658

<i>Quinupristin/dalfopristin</i>	659	Targeting Protease Production	685	Paraneoplastic Opsoclonus/ Encephalopathy	727
<i>LY 333328</i>	659	<i>Peptidyl methyl ketone</i>	685	Progressive Multifocal Leukoencephalopathy	727
<i>Daptomycin</i>	660	<i>Marimastat</i>	685		
<i>Linezolid</i>	660	<i>Carboxy-amido-triazole (CAI)</i>	685		
<i>Ziracin</i>	660	MECHANISMS OF DRUG-INDUCED APOPTOSIS	685	ADVANCES IN THE MANAGEMENT OF GASTROINTESTINAL CANCER	
<i>Other agents</i>	660	TELOMERASE IN CANCERS OF THE NERVOUS SYSTEM	687	FROM THE 62ND ANNUAL SCIENTIFIC MEETING OF THE AMERICAN COLLEGE OF GASTROENTEROLOGY (ACG) CHICAGO, IL; NOVEMBER 3-5, 1997	
Vancomycin-Intermediate <i>Staphylococcus aureus</i>	660	HERPES VECTORS FOR BRAIN TUMOR THERAPY	687	BARRETT'S ESOPHAGUS	753
Methicillin-resistant <i>Staphylococcus aureus</i>	660	Basic HSV Gene Therapy Vector	693	Prevalence of Short-Segment Barrett's Esophagus (SSBE)	753
Other Bacterial Infections in Cancer Patients	660	Improved HSV Recombinant Vector	693	Diagnosis and Treatment of SSBE	753
<i>Penicillin-resistant Streptococcus pneumoniae</i>	660	HSV-1 Amplicon	693	PREVENTION AND TREATMENT OF ESOPHAGEAL CANCER	753
<i>Stenotrophomonas maltophilia</i>	660	Helper Virus-free Packaging System	694	Photodynamic Therapy	753
<i>Pseudomonas aeruginosa</i>	661	FARNESYL TRANSFERASE INHIBITORS AND ANTI-RAS THERAPY	694	<i>Barrett's dysplasia</i>	753
FUNGAL INFECTIONS	661	TARGETING P53-DEFICIENT CELLS WITH ADENOVIRUS MUTANTS	695	<i>Refractory adenocarcinoma of the distal esophagus</i>	753
Candida Fungi	661	A REPORT ON MOLECULAR MEDICINE OF CANCER, A GENETIC DISEASE		<i>Beta-carotene</i>	753
Zygomycosis	661	FROM THE NINTH ANNUAL USHA MAHAJANI SYMPOSIUM AT THE SALK INSTITUTE, SEPTEMBER 5, 1997		Stents	754
Fusarium	661	METHYLATION AND EPIGENETIC INSTABILITY IN THE DEVELOPMENT OF CANCER	696	GASTRIC CANCER	754
Antifungals in Development	662	Imprinted Genes and Childhood Tumors	696	Neoadjuvant Chemotherapy	754
<i>Nyotran</i>	662	Methylation of Normal Genes	696	COLORECTAL CANCER	754
<i>Echinocandin derivatives</i>	662	Hypermethylation	696	Benefits of Screening	754
<i>SCH 56592</i>	662	<i>Mismatch repair genes</i>	696	Colon Cancer Prevention	754
<i>Sordarin derivatives</i>	662	<i>Epimutations</i>	697	<i>Difluoromethylornithine (DFMO)</i>	754
Novel Antifungal R&D Programs	662	<i>Loss of a protective mechanism</i>	697	<i>Aspirin</i>	755
<i>RiboGene</i>	662	CHROMOSOMAL TRANSLOCATIONS IN CANCER	697	Argon Plasma Coagulation of Colorectal Adenomas	755
<i>Millennium Pharmaceuticals</i>	663	Bcl-2	697		
<i>Alpha-Beta Technology</i>	663	Genes Involved in the Pre- initiation of Cancer	697	ADVANCES IN THE MANAGEMENT OF HEMATOLOGIC MALIGNANCIES	
THERAPEUTIC APPROACHES FOR OPPORTUNISTIC INFECTIONS	663	EMERGING CYTOGENETIC TECHNOLOGIES TO DETECT QUANTITATIVE CHROMOSOME CHANGES	698	FROM THE 39TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) SAN DIEGO, CA; DECEMBER 5-9, 1997	
Bacterial Infections	663	BRCA1 AND BRCA2 GENES IN BREAST AND OVARIAN CANCER	698	ACUTE MYELOGENOUS LEUKEMIA (AML)	755
<i>Cefepime</i>	663	Mutations Vary by Geography	698	Maxamine and IL-2 Combination Therapy	755
<i>Ciprofloxacin</i>	664	Actionable Cancer-propensity Genes	698	IL-2 Monotherapy	755
Viral Infections	664	Sporadic Cancers	699	ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)	756
<i>Penciclovir</i>	664	Gene Therapy	699	Shortened, Intensified Chemotherapy	756
Fungal Infections	665	NEW THERAPEUTIC APPROACHES IN NEURO-ONCOLOGY		ACUTE PROMYELOCYTIC LEUKEMIA (APL)	756
<i>Liposomal amphotericin B</i>	665	FROM THE 49TH ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY BOSTON, MA, APRIL 12-19, 1997		Concurrent Induction Chemotherapy and All-trans Retinoic Acid (ATRA)	756
<i>Aerosol amphotericin B prophylaxis</i>	665	GLIOMAS	725	CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	756
<i>Fluconazole</i>	665	Interferon β -1A	725	Cladribine	756
<i>Granulocyte-macrophage colony stimulating factor</i>	666	Multimodality Regimens	726	CHRONIC MYELOGENOUS LEUKEMIA (CML)	756
<i>Voriconazole</i>	666	High-dose Chemotherapy	726	Decitabine	756
<i>Itraconazole oral solution</i>	666	CNS LYMPHOMAS	726	MYELOYDPLASTIC SYNDROME (MDS)	757
<i>Azole-based prophylaxis</i>	666	PARANEOPLASTIC NEUROLOGICAL SYNDROMES	727	Topotecan	757
New Spectrum of Opportunistic Infections in Fludarabine- Treated CLL	666			Amifostine in Combination Therapy	757
Fungal Pneumonia	667			LYMPHOMAS	757
COSTS ASSOCIATED WITH ANTI-INFECTIVE THERAPY IN NEUTROPENIC PATIENTS	667			Poor Prognosis Malignant Lymphoma	757
				Non-Hodgkin's Lymphoma (NHL)	758
CANCER OF THE CENTRAL NERVOUS SYSTEM				MULTIPLE MYELOMA	758
FROM THE AMERICAN ASSOCIATION OF CANCER RESEARCH CONFERENCE JUNE 7-11, 1997, SAN DIEGO, CA					
TARGETING REGIONAL METASTASES OF BRAIN TUMORS	684				

Interferon- α Maintenance	758
Clarithromycin	758
TREATMENT OF CHEMOTHERAPY-INDUCED SIDE EFFECTS	758
Thrombocytopenia	758
Mucositis	759
<i>Recombinant keratinocyte growth factor</i>	759

REPORT FROM THE SIXTH INTERNATIONAL CONFERENCE ON GENE THERAPY OF CANCER

SPONSORED BY THE SIDNEY KIMMEL CANCER CENTER
 NOV 19-22, 1997, SAN DIEGO, CA

APOPTOSIS AND GENE THERAPY	770
P53	772
Introgen Therapeutics	775
<i>Phase I clinical trials in head and neck cancer</i>	775
<i>Phase I studies of INGN 201 for treating non-small cell lung cancer</i>	775
<i>Ovarian cancer</i>	776
<i>Preclinical studies of p53 replacement gene therapy for pancreatic cancer</i>	776
<i>Tumor regression in vivo following p53 combination therapy</i>	776
Canji (Schering-Plough)	777
<i>Phase I clinical trials of intrahepatic SCH 58500</i>	777
<i>Adenovirus-mediated p53 gene therapy synergizes with paclitaxel</i>	777
Onyx Pharmaceuticals	778
<i>Phase I clinical trial of ONYX-015</i>	778
<i>Preclinical studies with ONYX-015 in combination with chemotherapy</i>	778
CELL CYCLE-BASED GENE THERAPY	779
HepaVec	779
Canji	780
BCL-2	780
JNK/SAPK PATHWAY	781
Isis Pharmaceuticals	781
OTHER GENE THERAPY APPROACHES	781
Inhibition of Nude Mice Xenografts Using Growth Inhibitory Gene Mda-7	781
Anti-papillomavirus Ribozymes	782
Anti-ras and Anti-raf Approaches	783
Apoptin	783
Interleukin-1 β Converting Enzyme (ICE)	783
SUICIDE GENE THERAPY STRATEGIES	783
Target Selectivity	783
Pre-emptive Suicide Gene Strategies	783
Herpes Simplex Virus Thymidine Kinase (HSV-tk) Gene Combined with the Prodrug Ganciclovir (GCV)	784
<i>Phase II clinical trials of GLI 328 HSV-Tk gene therapy in recurrent glioblastoma</i>	784

<i>A series of phase I clinical trials adenoviral-based gene therapy for malignant mesothelioma with concomitant immunosuppression</i>	784
<i>Noninvasive imaging of adenoviral-mediated HSV-tk gene transfer and expression</i>	785
Other Prodrug Activating Gene Therapy	785
<i>Mutant HSV-1 tk combined with acyclovir (ACV)</i>	785
<i>New enzyme/prodrug combinations for use in gene-directed enzyme prodrug therapy (GDEPT)</i>	786
THE BYSTANDER EFFECT	786
Evaluation of Adenovirus p53-mediated Bystander Effect <i>In Vivo</i>	786
Bystander Effect in HSV-Tk Suicide Gene Therapy	786
IMPROVING DELIVERY APPROACHES	787
Enhancing Nonviral Delivery	787
Vaccinia Virus	787
Tumor-specific Ligand-liposome Gene Delivery	787

MECHANISMS IN MALIGNANCY

THE CELL CYCLE

CELL CYCLE CONTROL	591
Growth Signals	591
Cyclins and Cyclin-dependent Kinases	591
<i>Targets of cyclins and cdk</i>	592
Mechanism of Action of the Retinoblastoma (Rb) Tumor Suppressor	592
<i>E2F regulation by cell cycle-dependent changes in subcellular localization</i>	593
<i>Molecular mechanisms of E2F transcriptional regulation</i>	593
Cyclins/cdk Regulation	594
CELL CYCLE DYSREGULATION AND CANCER	594
Cellular Response to Oncogenic Mutation	595
p53	595
<i>The role of p57 (Kip2)</i>	595
Apoptosis	596
Viral Oncogenes	596
DIAGNOSTIC/PROGNOSTIC APPLICATIONS OF CELL CYCLE	596
Cascade Oncogenics	596
CELL CYCLE MODULATION AS AN ANTI-CANCER STRATEGY	597
Direct Inhibitors of Cyclin:cdk	597
<i>Flavopiridol</i>	597
<i>Olomoucine and roscovitine</i>	598
Inhibitors of Activation or Activators of Inhibition of Cdk	598
Activators of Cyclin:cdk Proteolysis	598

Transcriptional Factors	598
Chemoprotection	598
Chemosensitization	598
UCN-01	598
DRUG DEVELOPMENT AND RESEARCH PROJECTS	599
Small Molecule Drugs	599
Mitotix	599
Onyx	599
ProScript	599
Sugen	599
Peptide Mimetics	599
Cyclacel	599
Oligonucleotide-based Drugs	600
Gilead Sciences	600
Genomics	600
Ventana Genetics	600
Other	600
Icos	600

ANTI-CANCER DRUG DEVELOPMENT

TAXANES — PART I STATUS OF TAXANES AND THE OUTLOOK FOR GENERIC VERSIONS OF PACLITAXEL

CLINICAL ISSUES	614
Taxol	615
Taxotere	615
Paxene	615
TAXOL PATENT AND EXCLUSIVITY ISSUES	615
APPROVED/MARKETED GENERIC VERSIONS OF PACLITAXEL	616
Suppliers of Paclitaxel to Drug Companies	616
Hauser	616
Indena	617
NaPro BioTherapeutics	617
Marketers of Generic Paclitaxel	619
Dabur	619
F. H. Faulding	619
Immunex	620
Yew Tree Pharmaceuticals	620

TAXANES — PART II INDICATIONS, MARKETS, FORMULATIONS, ANALOGS AND DERIVATIVES, AND NOVEL SPINDLE POISONS

CLINICAL STATUS	635
Ovarian Cancer	635
Breast Cancer	635
Kaposi's Sarcoma	635
Lung Cancer	637
Combination Regimens	637
TECHNICAL CHALLENGES	637
Biomass Sources	637
Formulations	637

Administration Routes	637	ChiRex	638	Phytogen Life Sciences	639
MARKET OPPORTUNITY	637	Gensia Sitor	638	Sparta Pharmaceuticals	639
PACLITAXEL EXTRACTS AND SEMI-SYNTHETIC VERSIONS	638	Phytogen Life Sciences	638	SuperGen	639
Aphios	638	Samyang Genex	639	Xechem International	640
Biolysse Pharma	638	Wex	639	NEXT GENERATION OF TUBULIN STABILIZING DRUGS/SPINDLE POISONS	640
BioNumerik Pharmaceuticals	638	NOVEL DRUG DELIVERY SYSTEMS	639	Epothilones	640
Bio-Technology General	638	Guilford Pharmaceuticals	639	Eleutherobin	641
Cytoclonal Pharmaceutics	638	Matrix Pharmaceuticals	639	RPR-109881	641
		NeoPharm	639		

LIST OF EXHIBITS

TITLE	PAGE				
Number of In-patient Ovarian Procedures in the USA	546	Estimated Stage Distribution of Oral Cavity and Pharynx Cancer at Time of Diagnosis by Gender in the USA 1997	628	Estimated Incidence of Pediatric (Ages 0-19) Primary Brain Tumors by Histology Group and Gender in the USA	688
Surgeries and Outlays for Ovarian Cancer in Medicare Patients in 1995	547	Estimated Five Year Survival Rates of Oral Cavity and Pharynx Cancer by Gender in the USA, 1997	629	Estimated Incidence of Metastatic Brain Cancer by Primary Tumor in Selected World Regions in 1997	689
Women Administered Chemotherapy for Ovarian Cancer in Selected World Regions in 1995	550	Estimated Five Year Survival Rates for Oral Cavity and Pharynx Cancer in Major World Regions, 1997	630	Molecular Markers for Brain Tumors and Cancer of the Central Nervous System	690
Chemotherapeutics Approved Worldwide for the Treatment of Ovarian Cancer	552	Correlation of Selected Growth Factor Expression and Survival in HNSCC	631	Five-Year Survival Trends of Brain and Nervous System Cancer Cases in the USA	694
Recently Reported Results from Various Clinical Trials in Ovarian Cancer	555	Estimated Chemotherapy Treatment Regimens for Head and Neck Cancer in Selected World Regions in 1997	632	Estimated Incidence, Two- and Five-Year Relative Survival for Malignant Brain Tumors by Histology Group	695
Active Ongoing Clinical Trials for the Treatment of Ovarian Cancer	558	Worldwide Candidate Populations for Taxane-based Chemotherapy	636	Five-Year Survival Rates for Brain and Nervous System Cancer in the USA in 1997	697
Screening/Diagnostic Tests on the Market and/or in Development for Cervical Cancer	563	Response Rates Associated with Taxane Therapy	640	Incidence and Five-Year Survival of Brain and Nervous System Cancer in Selected World Regions by Stage at Diagnosis	699
Diagnostic Triage with Pap and HPV Testing	566	Chemotherapy Regimens in Current Clinical Trials in HNSCC	649	Surgical and Other Ablative Techniques in the Treatment of Brain Tumors	704
Selected Agents in Development for the Treatment of Ovarian Cancer	572	Drugs in Development for the Treatment of Head and Neck Cancer	652	Estimated Radiation Therapy Cases of Primary CNS Cancer by Major World Regions	706
Estimated Potential Market for Therapeutic and Prophylactic Vaccines for Ovarian Cancer in Selected World Regions	585	Cost comparison of Inpatient Antibiotic Regimens in Neutropenic Patients	667	Radiotherapy Techniques in Clinical Use	708
Estimated Incidence and Mortality of Oral Cavity, Pharynx and Larynx Cancer in Major World Regions in 1997	607	Estimated Worldwide Incidence of Primary Brain and Nervous System Cancer in 1997	671	Estimated Chemotherapy Cases of Primary CNS Cancer by Major World Regions	710
Estimated Worldwide Incidence of Head and Neck Cancer (Oral Cavity and Pharynx) in 1997	608	Estimated Worldwide Mortality of Primary Brain and Nervous System Cancer in 1997	673	Commercially Available Therapeutics for the Treatment of CNS Cancer	711
Estimated Worldwide Mortality of Head and Neck Cancer (Oral Cavity and Pharynx) in 1997	611	Types of Benign and Primary Malignant Tumors of the CNS	676	Ongoing Clinical Trials with Commercially Available Chemotherapeutics for CNS Cancer	713
Estimated Incidence of Head and Neck Cancer (Oral and Pharynx) and Distribution by Site	613	Estimated Annual Incidence of Primary Brain Tumors by Site and Gender in the USA	680	Standard and Emerging Treatment Approaches For Primary and Metastatic CNS Tumors by Histology Group in the USA	719
Estimated Number and Percent of New Cases and Deaths by Specific Head and Neck Cancer Sites in North America (1997)	614	Estimated Breakdown of Primary and Metastatic Adult Brain Tumors by Site in the USA	681	Outcome of Children with CNS Tumors by Type	724
Relative Five Year Survival Rate of Head & Neck Cancer by Race in the USA	613	Incidence Rate of Brain and Nervous System Cancer by Race and Gender Over Two Decades in the USA	685	Worldwide Incidence and Mortality of Prostate Cancer in 1998	732
Molecular Markers Associated with Head and Neck Cancer	616	Estimated Incidence of Primary Brain Tumors by Major Histology Groups and by Gender in the USA	686	Age-specific Incidence of Prostate Cancer in Selected World Regions in 1998	735
Taxol Chronology	618	Estimated Incidence of Pediatric Primary Brain Tumors by Gender and Age Group in the USA	687	Estimated Age-specific Prevalence of Latent Prostate Cancer in Selected World Regions in 1998	736

Incidence Trends of Prostate Cancer in the USA	737	Drugs in Development for Treatment of CNS Cancer	740	PSA Tests on the Market and/or in Development	767
Mortality Trends of Prostate Cancer in the USA	738	Types of PSA Tests	763	Worldwide PSA Markets in 1997	771
Incidence and Mortality Rates of Prostate Cancer in the USA by Race and Ethnicity	739	Total PSA Tests Performed in all Men and in Men Over Age 65 Between 1990 and 1997 in the USA	765	Prostate Cancer Markers	773
				Gene Therapy Agents in Development by Introgen Therapeutics	776

INDEX OF COMPANIES & INSTITUTIONS

Aastrom Bioscience	572	Banyu	573	Cancer Research Campaign (CRC) Centre for Cancer Therapeutics	574, 590, 599, 600, 745, 786	Cortecs	574, 590, 628
Abbott Laboratories	579, 657, 662, 750, 757, 762, 764, 767	Bard Diagnostic Sciences	764	Cancer Research Campaign Technology (CRTC)	599, 628, 736	Coulter Pharmaceuticals	758
Abic	552	Bard Urological	764	Cancer Therapeutics	573, 587, 588	Creighton University School of Medicine	547
AccuMed International	563	Bar-Ilan Research and Development	572	Cancer Therapy and Research Center	572	Cross Cancer Institute (CCI)	585, 714, 716
Accuray	704	BASF	576, 599	Canji	573, 651, 652, 740, 777, 780	Cubist Pharmaceuticals	660
Advanced Biological Systems (ABS)	733, 740	Bavarian Nordic Research Institute	740	CarboMed	573	Cyclacel	599, 600
Agouron Pharmaceuticals	572, 622, 641, 650, 652	Bayer	563, 664, 757	Cascade Oncogenics	596, 597, 769	Cytel	574
Alamar Biosciences	563	Bayer Diagnostics	762, 763, 764, 767	Case Western Reserve University	558	Cytoclonal Pharmaceuticals	638
Alkermes	740, 752	Baylor College of Medicine	595, 721	Castelfranco	713	Cytogen	735, 745, 764, 769
Allergan Ligand Retinoid Therapeutics (ALRT)	572	Beaufour Ipsen	648	Catholic University	714, 718	Cytc	563, 564
Allos Therapeutics	738, 740	Beckman Coulter	764	CDR Therapeutics	573, 586, 587	Dabur	619
Almirall	552	Beckman Research Institute of the City of Hope	558, 559, 560, 561	Cedar Sinai Medical Center	748	Daiichi Pharmaceuticals	552, 574
Alpha-Beta Technology	663	Behring Diagnostics	767	Cel-Sci	652, 655	Dainippon Pharmaceutical	577
Alta Partners	587	Berlex	666, 757, 725	Cell Genesys	574, 579, 744	Damon Biotech	750
AltaRex	572, 584, 585	Bernardo Houssay Hospital	573, 652	Cell Therapeutics	574, 656	Dana-Farber Cancer Center	589
Alza	552, 553, 740, 752, 757	Beth Israel Deaconess Medical Center	709	CellPro	576, 718	Dana-Farber Cancer Institute	560, 709, 746
AMD	767	Binary Therapeutics	709, 743	Celltech Therapeutics	574	Dartmouth Medical School	576, 653, 742
American Home Products	554, 574, 617	BioChem Pharma	574	Center for Molecular Medicine and Immunology (CMMI)	575, 588	Darwin Discovery	785
American Red Cross	652	BioChem Therapeutic	580, 743	Centers for Disease Control and Prevention	659	David Bull Labs	619
Amgen	584, 731, 749, 759	Biogen	725, 740	Centocor	773	Debiopharm	571, 574
Ampersand Ventures	563	Biolyse Pharma	619, 635, 637, 638	Centre de Recherche pour les Pathologies Prostatiques (CEREPP)	765	Degussa	653
Anchor Advanced Products	572	Biomerica	767	Centre Leon Berard	713	Denu	563
Anika Therapeutics	572, 589	Biomira	572, 573, 584, 585, 586	Cephalon	574, 737, 740	DepoTech	574, 717, 718
Ansan	572	Biopharmaceutics	733, 740	ChemGenics Pharmaceuticals	663	DiagnoCure	774
Anthra Pharmaceuticals	570, 572	Boehringer Ingelheim	648, 653	ChiRex	619, 638	Diagnostic Decisions	768
AntiCancer	572, 581, 582	Boehringer Mannheim	573, 652, 656, 768, 769	Children's Hospital at Harvard Medical School	741	Diagnostic Products Corporation	762, 767
Anti-Cancer Center Paul Strauss	567	Bombay Hospital	716	Children's Hospital of Philadelphia	740	Diagnostic Systems Laboratories	767
Antigenics	572	Boston Scientific	754	Chino	740	Dianon	767, 768
Antisoma	573, 587, 588	Boron Biologicals	706	Chiron	573, 574, 576, 586, 656, 717, 741, 747, 750	Digene	563, 564
Aphios	638	BrainLAB	704, 705	Chiron Diagnostics	764, 767	Dillion, Read Ventures Capital	599
Aphton	572	Briana Bio-Tech	740	Chiroscience	785	DPC Bierman	762, 767
Appex Technologies	585	Brigham and Women's Hospital	704, 707, 709, 716	Cholestec	767	Draxis Health	638
Apothecon	665	Bristol-Myers Squibb (BMS)	548, 549, 552, 553, 566, 567, 571, 573, 579, 599, 614, 616, 617, 618, 619, 620, 635, 637, 639, 641, 642, 650, 658, 663, 710, 711, 712, 723, 733, 734, 735, 739, 740, 744, 746, 778	CHU	716	Drug Royalty	638, 639
Aquila Biopharmaceutics	744	British Biotech	567, 573, 685, 740, 745, 746	Chugai	553, 578, 635	Duke Comprehensive Cancer Center	712, 715
Arch Partners	587	British Columbia Cancer Agency (BCCA)	585	Ciba Corning Diagnostics	767	Duke University	576, 741, 744, 746
Ares Serono	552	British Columbia Children's Hospital	715	Ciba-Geigy	576	Dundee University	600
Arizona Cancer Center	578, 580	Brookhaven National Laboratory	706	CIS biointernational	767	DuPont Merck Pharmaceuticals	599
Arizona State University	580	Buenos Aires University	565, 573, 652	Cleveland Clinic	715, 731	Eastern Cooperative Oncology Group (ECOG)	559, 636
Arkansas Cancer Research Center	658	Burnham Institute	770	Clinique de Pediatrie (Geneva, Switzerland)	716	Edith Norse Rogers Memorial Veterans Hospital	785
Aronex Pharmaceuticals	573, 580, 662	Burr Egan Deleage	587	Cobe BCT	572	EG&G Wallac	762, 767
ArQule	662	C.R. Bard	764	Cold Spring Harbor Laboratories	751	Elan	735, 745, 764
Arris Pharmaceutical	685	Calydon	573	Colorado State University	663	Elekta Instruments	704
Ascalon	586	Cambridge Antibody Technology (CAT)	745, 751	Columbia University	562, 575, 751, 781	Eli Lilly	552, 567, 574, 576, 577, 581, 650, 659, 660, 662, 664
Asta Medica	573, 579, 653	Cambridge Neuroscience	578	CompuCyte	563	Elscint	683
Astra Merck	753			Corange International	652, 656	Emory University	736
Austin Research Institute	575			Corixa	574, 586	EntreMed	741, 746
AutoCyte	563					Environmental Protection Agency	637
AVAX Technologies	573, 585, 740, 749					Enzon	647, 652
Axys Pharmaceutical	685					EORTC	559, 565
Azienda Ospedaliera	716						
Baker Norton Pharmaceuticals	549, 571, 615						

Ergo Science	589, 741	Hotel Dieu de Montreal Hospital	638	Lady Davis Institute for Medical Research	655	Montana College of Mineral Science and Technology	638
ESCAgenetics	639	Houghten Pharmaceuticals	662	Laserscope	753	Montana State University	638
Ethox	572	Howmedica Leibinger	705	Lederle Japan	648, 664	Morningstar Diagnostics	768
F. H. Faulding	549, 552, 571, 619, 637	Human Genome Sciences	766, 774	Leica Microscopy and Systems	563	Mortimer B. Davis Jewish General Hospital	565, 655
Florida State University	618	Humboldt University	779	Leiden University	783	Mount Sinai School of Medicine	572
Food and Drug Administration (FDA)	563, 564, 585, 590, 615, 616, 619, 620, 635, 636, 637, 638, 640, 762, 767, 768	Hyal Pharmaceutical	652, 656	Lescarden	576, 653	Myco Pharmaceuticals	663
Fordham University	572	Hybritech	762, 763, 764, 767, 768, 769	Lexigen Pharmaceuticals	742, 750	MycoTox	663
Foshan Faulding	552, 619	Iatron Laboratories	768	Ligand Pharmaceuticals	576, 648, 650, 653, 740	Mylan Pharmaceuticals	638
Fournier (Laboratoires)	580	Icos	600	Lineberger Comprehensive Cancer Center UNC	560	Myriad Genetics	577, 751, 765
Fox Chase Cancer Center	583	IDEC Pharmaceuticals	575, 731, 741, 758	Linz-Roberts	707	Nagoya University	740
Fred Hutchinson Cancer Research Center	559, 686	Ilex Oncology	648, 741, 754	The Liposome Company	665	Nanning Maple Leaf Pharmaceutical	639
Fuji ImmunoPharmaceuticals	742, 750	Ilexus	575	Loma Linda University	708	NaPro BioTherapeutics	549, 552, 571, 615, 617, 619, 637
Fujisawa	665	ImClone Systems	575, 602, 643, 652, 654	Loma Linda University School of Medicine	787	National Center for Human Genome Research (NCHGR)	766
Garden State Cancer Center	588	Immune Response	741, 748	Loma Ontario Regional Cancer Center	638	National Cancer Institute (NCI)	552, 553, 558, 560, 562, 573, 575, 576, 577, 578, 580, 587, 597, 598, 599, 618, 635, 641, 643, 652, 653, 670, 685, 707, 715, 732, 733, 734, 735, 736, 737, 738, 740, 741, 742, 743, 744, 745, 746, 747, 775
GE Medical Systems	708	Immunex	554, 572, 575, 601, 602, 617, 619, 620, 666, 712, 756	Louisiana State University School of Medicine	786	National Human Genome Research Institute (NHGRI)	766
Gene Logic	765	Immuno-Biological Laboratories	768	Ludwig Institute for Cancer Research	574	National Institutes of Health (NIH)	552, 562, 575, 577, 578, 734, 735, 738, 741, 743, 756, 773, 784, 785
GeneMedicine	652, 656	Immunomedics	575, 588	Ludwig-Maximilians-Universität	653	National Testing Laboratories	563
Genentech	574, 637, 758	Immutec	619	Lund University	762	NCI Division of Cancer Treatment, Diagnosis and Centers	647
Genetic Therapy	575, 741, 750, 782, 784	Imperial Cancer Research Fund (ICRF)	575, 587, 588	Lundbeck	552	Nehoc	585
Genetix Pharmaceuticals	575, 584	Imperial Cancer Research Technology (ICRT)	740	M. D. Anderson Cancer Center	558, 560, 575, 576, 578, 580, 584, 590, 640, 651, 652, 653, 661, 662, 746, 705, 713, 714, 715, 716, 751, 776	NeoPath	563
Genetronics	652, 657, 741, 752	Imperial College	663	Magainin Pharmaceuticals	742	NeoPharm	577, 639, 707, 738, 743
GenQuest	781	Indiana University School of Medicine	576	Magenta Pharmaceuticals	584	NeoRx	577, 588
Genset	765	Indigo Medical	646	Mallinckrodt Medical BV	683	The Netherlands Cancer Institute	631
Gensia Sicor	638	Inex	576	Massachusetts General Hospital (MGH)	588, 689, 708	Neurobiological Technologies	725, 743
Genzyme	575, 780	Ingenex	576, 584	Massachusetts Institute of Technology (MIT)	563, 593, 639, 706	Neurological Systems	564
Genzyme Molecular Oncology	780	InNova	619	Matritech	563, 768	New York University Medical Center	579
Genzyme Transgenics	580, 586	Instent	754	Matrix Pharmaceuticals	576, 639, 653	NeXstar Pharmaceuticals	577, 578, 639, 665
Georgetown University	574, 580, 639, 746	Institut für Klinische Hamatologie	576	Max-Planck Society	579	Nikon	563
Gesellschaft für Biotechnologische Forschung	641	Institute for Cancer Research	574, 590, 652, 655	Maxim Pharmaceuticals	755	Nippon Kayaku	573
Gilead Sciences	600	Institute of Virology	740	Mayo Clinical Cancer Center	559, 714, 716, 724	Nomos	708
Glasgow University	600	Instituto de Ricerche di Biologia Molecolare	602	McGill University	565, 638, 768	Norris Cotton Cancer Center	557, 715
Glaxo Wellcome	552, 553, 554, 575, 581, 599, 600, 642, 650, 660, 662, 664, 718, 758, 786	Intermountain Health Care	558	Mead Johnson Oncology	552	Norwegian Radium Hospital	713
Goodwin Biotechnologyx (GBI)	580, 586	International Isotopes (I ³)	705	Medac	552, 572, 584	Nova Therapeutic Systems	704
Grupo Ferrer Internacional	662	Introgen Therapeutics	576, 642, 651, 652, 653, 654, 769, 775, 776, 777	Medarex	576, 653, 655, 742	Novartis	575, 576, 577, 583, 623, 641, 741, 743, 784
GSF-Forschungszentrum für Umwelt und Gesundheit	740	IntroGene	741	Medeva	570, 571, 572	Novopharm Biotech	743
Guilford Pharmaceuticals	639, 710, 711, 741	Ion Beam Applications	704	Medical Research Council (UK)	558	Nycomed Pharma	549, 554, 707, 742
Hafslund Nycomed	620	Ireland Cancer Center	558	MediCorp	768	Olympus America	563
Hamilton Regional Cancer Centre	655	Isis Pharmaceuticals	576, 781	Meditech	577	OncoAntigenics	572
Harvard Medical School	635, 704, 707, 708, 709	Ivax	549, 571, 615, 616, 635, 637	Medtronic	754	OncoRx	648
Harvard University	589, 599	Janssen Pharmaceutica	577, 588, 741	Meiji Seika Kaisha	660	OncoTech	577, 743
Hauser	616, 617, 618, 620, 637	Jefferson Medical College	697	Meiji Seika Pharma International	579	Onyx Pharmaceuticals	577, 599, 600, 653, 654, 695, 778
HealthCare Investment	599	Jefferson Medical College	697	Memorial Sloan-Kettering Cancer Center/Sloan-Kettering Institute for Cancer Research	558, 560, 574, 577, 597, 735, 714, 744, 746, 769, 784	OPG/Pharmachemie	549, 554, 620
Helsinki University Central Hospital	762	Jenner Technologies	576	Merck	658, 662, 663	Oregon Health Sciences University	597
Henry Ford Hospital	684	Jewish General Hospital in Montreal	638	MerckFrosst Canada	572, 584	Orion Pharma (Orion Farmos)	711, 741
HepaVec	779	John Wayne Cancer Institute	714, 737	Merck KGaA	653, 655, 742, 768	Ortho Biotech	656, 756
Herbert Irving Comprehensive Cancer Center	714	Johns Hopkins Oncology Center	560, 712, 714, 716, 735	Merck Research Laboratories	694	Osaka University Medical School	734, 745
HFR Unit, JRC-IAM, European Commission	706	Johns Hopkins University	579, 639, 672, 696, 742, 766, 768	Merlin Ventures	599, 600	Ottawa Regional Cancer Centre	714
Hoechst Celanese	647, 653	Johnson & Johnson	588, 646, 656	metaGen	765	OUR Scientific International	704
Fine Chemicals	647, 653	Johnson & Johnson Development Corporation	584	Metastatin Pharmaceuticals	774	OXIGENE	578, 709, 743
Hoechst Marion Roussel	587, 598, 599, 658, 659, 660, 757	Kagoshima University	734, 745	MGI Pharma	577, 656	Pacific Biotechnologies	617
Hoffmann-La Roche	563, 572, 599, 660, 622, 650, 652, 656, 756	Kaiser Permanente	564, 565	Milkhaus Laboratory	577	Pacific Generation Technologies	617
Hokkaido University School of Medicine	783	Khepri Pharmaceuticals	685	Millennium Pharmaceuticals	663, 765	Pacific Northwest Research Foundation	769
Horus Therapeutics	767	King Faisal Specialist Hospital and Research Center	720	Miravant Medical Technologies	742		
Hospital Notre Dame	655	Kissei	656	Mitotix	599		
Hospital Saint-Louis	765	Knoll AG	576, 599	Montana Biotech	663		
		Kumamoto University School of Medicine	752				
		Kyowa Hakko Kogyo	553, 574, 598, 736, 742				

Pacific Pharmaceuticals (formerly Xytronyx)	709, 734, 743	Salpetriere Hospital	716	Terrapin Technologies	580, 583	University of Texas	558, 560, 575, 576, 579, 580, 583, 653, 661, 735, 743
Parke-Davis	578, 734, 735, 743	Samyang	639	Teva	552	University of Texas Health Science Center, San Antonio	718
Paterson Institute of Cancer Research	628	Samyang Genex	639	Texas Children's Hospital	721	University of Texas Southwestern Medical Center	658, 687
Pennsylvania State College of Medicine	738, 743	Sandoz	583	Theragenics	646	University of Utah	577
Pennsylvania State University	734, 743	Sanofi	571, 574, 623, 642, 647, 648, 653, 709, 741, 744	Therion Biologics	580	University of Washington	574, 586, 590, 698
Pfizer	660, 663, 665, 666, 754	Sanofi Diagnostics Pasteur	764	Thomas Jefferson University	573, 585	University of Western Ontario	713
Pharmachemie	549, 554, 756	Schering AG	571, 765	Titan Pharmaceuticals	580, 586	University of Wisconsin	593
Pharmacia & Upjohn	552, 553, 574, 575, 578, 599, 621, 656, 660, 712, 717, 718, 739, 742, 755, 757, 779	Schering-Plough	552, 573, 579, 599, 643, 651, 652, 655, 658, 660, 662, 736, 740, 744, 751, 777	Toronto Hospital	714	University of Vaudrois	742
Pharmacocycle	662	Schering-Plough Research Institute	777, 778	Toshiba America Medical Systems	681	University of Virginia	643
Pharmacocyclics	647, 653, 707, 743	Schneider	754	Tosoh	768	UroCor	765, 768, 774
Pharma Mar	578	Scotia Holdings	578, 648, 653, 744	Towers Phytochemicals	638	UroGenesis	769
Pharos Pharmaceutical	639	Scripps Institution of Oceanography	641	TPL Phytogen	638	U.S. Bioscience	552, 553, 656, 724, 733, 745
Phoenix Pharmaceuticals	743	Scripps Research Institute	618, 641, 742, 750	Transgene	580	Vanderbilt University	590
Physician's Reliance Network	778	SeaMED	572	Transmolecular	745, 747	Varian Associates	704
Phytogen International	638, 639	SepraChem	638	Trega Biosciences	662	Varian Oncology Systems	708
Phytogen Life Sciences	638, 639	Sequus Pharmaceuticals	554, 570, 571, 579, 636, 653, 665	Triangle Pharmaceuticals	731, 732, 733, 745	Ventana Genetics	600
Phyton	618	Seragen	579, 744	Trilex Pharmaceuticals	580, 586	Vertex Pharmaceuticals	580
PHYTOPharmaceuticals	639	Serono Laboratories	744	Trylon	564	Vical	574, 586, 653
Picker International	683	Shenzhen Boda Natural Product Company	638	Tufts University	572	VIMRX Pharmaceutical	734, 745
Pierre Fabre	553	Shimadzu	683	Tulane University	573, 786	Vincent T. Lombardi Cancer Center at Georgetown Medical Center	574, 580, 716, 746, 787
Princess Margaret Hospital for Children	713, 714, 715	Shionogi	572, 582	Tumor Immunology and Gene Therapy Center	783	Vion Pharmaceuticals	648, 653
Princeton University	602	Sidney Kimmel Cancer Center	576, 652, 653, 697, 741, 748, 770, 776, 781	Universal Medical Systems	704	Virginia Commonwealth University Medical College of Virginia	787
Prodesfarma	572	Siemens Medical Systems	682	Universitet i Umea	766	Vital Pharmaceutical Development	580
Progenics Pharmaceuticals	744	Siemens Medical Systems, Oncology Care Systems	708	University Hospital of Heraklion	667	Walden Laboratories	585
ProScript	599	Simmons Cancer Center	715	University of Alabama	575, 580, 588, 590, 643, 745, 747, 780	Walter Reed Army Institute of Research (WRAIR)	576
Prototek	685	Sittona Company BV	652	University of Alabama Comprehensive Cancer Center	716	Warner-Lambert	599, 654, 660
Purdue University	576	SmithKline Beecham	549, 553, 581, 664, 712, 757	University of Alberta	572, 740, 783	Washington State University Research Foundation	638
QLT PhotoTherapeutics	648, 653, 709, 753	Sofamor Danek Group	705	University of Arizona	578, 580	Washington University	592
Quantimetrix	768	Sofinnova	587	University of Bologna	714	Wayne State University	655
R.W. Johnson Pharmaceutical Research Institute	656	Somatix Therapy	579, 744	University of California	577, 733, 744, 749	West Virginia University	716
Rabin Medical Center at Tel Aviv University	655	Southern Research Institute	552, 709, 744	University of California, Irvine (UCI)	571, 577	Wex	639
Radionics	704	Southwest Oncology Group (SWOG)	559, 561	University of California, Los Angeles (UCLA)	546, 769	Whitehead Institute	579
Repligen	578	Sparta Pharmaceuticals	639, 653	University of California, San Diego (UCSD)	601, 652, 732, 744, 745, 750	World Health Organization (WHO)	562
Research Corporation Technologies (RCT)	578, 580	Speywood Pharmaceutical	648	University of California, San Francisco (UCSF)	694, 722, 740, 743, 749, 750, 777, 784	Wyeth-Ayerst	574, 575, 580, 602, 617, 620, 663
Research Triangle Pharmaceuticals	639	The Sprout Group	563, 587	University of Chicago	560, 576, 584	Xechem International	640
RGene Therapeutics	580	SRI	653	University of Cincinnati	651	Xenova	745
Rhône-Poulenc Rorer	549, 552, 553, 575, 578, 581, 614, 620, 621, 635, 641, 650, 652, 659, 711, 712, 741, 744, 769, 775	SRI International	707	University of Colorado	714	Yakult Honsha	552
Ribi ImmunoChem Research	573	State University of New York	782	University of Colorado Cancer Center	619	Yale Comprehensive Cancer Center	558
RiboGene	662	Staten Island University Hospital North	716	University of Colorado Health Sciences Center	619	Yale University	648, 653, 747
Roberts Pharmaceuticals	707, 742	Stehlin Foundation for Cancer Research	575	University of Dundee	599, 600	Yang	768
Roche	708	Strong Memorial Hospital	712	University of Iowa	716	Yew Tree Pharmaceuticals	549, 554, 619, 620, 637
Roche Diagnostic Systems	768	Sugen	579, 587, 599, 653, 738, 744	University of Kentucky	580, 586	Zelenka Nursery	617
Roche Holdings	769	Sun Hill Glucose	639	Research Foundation	580, 586	Zeneca	573, 622, 653, 654, 665
Roche Image Analysis Systems (RIAS)	563	SUNY at Buffalo School of Medicine	713	University of Lund	709, 762		
Roger Bellon	552	SuperGen	639, 640	University of Michigan	572, 653		
Roswell Park Cancer Institute	602	Supratek Pharma	744, 752	University of Montreal	638		
The Rowland Institute	741	Surgical Navigation Technologies	705	University of Pennsylvania	573, 587, 745, 749, 784		
Royal Marsden Hospital	574, 590	Synthelabo	765	University of Pittsburgh	580, 653, 656, 768, 769		
Royal Prince Alfred Hospital	716	Taiho Pharmaceutical	580, 583, 734, 745	University of Rochester	724		
RPR GenCell	576, 584, 642, 651, 652, 653, 775	Takara Shuzo	659	University of Rome La Sapienza	661		
Rush Presbyterian St. Luke's Medical Center	657	Takeda	579, 744, 746, 764	University of Southern California (USC)	557, 635, 694, 748		
Saint Joseph's Hospital and Medical Center	588	Tanabe Seiyaku	573, 740, 746	University of Southern California at San Diego	636		
Saint Jude Children's Research Hospital	715	TAP Pharmaceuticals	579, 744, 746, 764	University of South Florida	657		
		Targeted Genetics	580	University of Tennessee Research Corporation (UTRC)	580		
		Targon	735, 745, 764				
		Techniclone	745, 751				

NOTE:
OUR AREA CODE HAS
BEEN CHANGED

TELEPHONE:
(949) 830-0448

FAX:
(949) 830-0887

REPORTS

CANCER PAIN: WORLDWIDE PRODUCT DEVELOPMENT AND MARKET OPPORTUNITIES

REPORT #430 SEPTEMBER 1998 250 PAGES \$3,450

One of the most debilitating complications of cancer is moderate to severe chronic pain. Ignored in the past, new guidelines call for aggressive treatment of such pain and are encouraging physicians to co-operate with their patients to achieve satisfactory control. Currently, the most effective agents in the treatment of cancer pain are opioids but considerable R&D effort is underway to discover and commercialize alternative pharmacologic treatments promising to improve the quality-of-life of chronic pain sufferers irrespective of the origin of pain. This report provides a comprehensive review of all aspects of cancer pain as outlined below:

Section I describes the basic mechanisms involved in pain

Molecular Biology of Pain (pain receptors and signal transmission pathways)

Anatomy of Pain Perception (peripheral receptors, spinal cord, brain regions and pathways)

Types of Cancer-Related Pain (bone, breakthrough, central, neuropathic, nociceptive, phantom and treatment-related pain)

Physiology and Pathogenesis of Pain (cancer types and special populations)

Section II provides a worldwide epidemiology of incidence, prevalence and morbidity associated with cancer pain by origin and world region (North America, Europe, Japan and ROW) and assesses its economic and quality-of-life impact.

Section III describes diagnostic and management approaches by origin of pain

Tumor-related Chronic Pain Syndromes

Treatment-related Chronic Pain Syndromes

Section IV delineates current treatment approaches

Pharmacologic Interventions (NSAIDs, morphine/opioids, methadone, corticosteroids, alpha adrenergic agonists, anticonvulsants, antidepressants, neuroleptics, biphosphonates/calci-tonin, antineoplastics, muscle relaxants, antihistamines, psychostimulants, etc.)

Radiation Therapy (treatment of bone metastases by localized, wide-field, stereotactic and fractionated radiotherapy and radiopharmaceuticals)

Surgery and other Approaches (neurosurgery, nerve blocks, acupuncture, psychosocial interventions)

Section V describes drug delivery methodologies in use or in development to enhance administration of pain medications, including oral controlled/sustained release, rectal, transdermal, nasal/inhaled, injectable, intrathecal/intraspinal (temporary/permanent catheters, subcutaneous injection ports/reservoirs, implantable pumps, intraventricular delivery, patient-controlled analgesia, encapsulated cells, etc.) and subarchnoid delivery.

Section VI provides a detailed review of R&D involving significant improvements of existing drugs such as opioids and non-opioids as well as novel agents based on newly-discovered mechanisms, including ion channel blockers, afferent neurons, ligand/receptor interactions (neurotransmitters, NMDA antagonists, neuropeptides, cholecystokinin antagonists, etc.), anti-hypersensitivity agents, etc. This Section also incorporates a comprehensive database of analgesics in development worldwide, listing the agent's developer/ affiliate, mechanism/technology and clinical status.

Section VII estimates current worldwide markets for pain management products and identifies major opportunities for cancer-pain medications.

Section IX profiles over 40 developers of pain-related products.

CANCER VACCINES: TECHNOLOGY, PRODUCTS, MARKETS AND BUSINESS OPPORTUNITIES

REPORT #401 250 PAGES OCTOBER 1997 \$1,950

Increased understanding of the immune system coupled with genetic engineering and other cutting-edge technologies, is encouraging the development of a new generation of vaccines using diverse approaches. A new round of prototype tumor vaccines is expected to advance in clinical trials in the next two to three years. Some vaccines represent a broad-based approach, attempting to trigger the whole immune system, while others are directed at specific targets. If successful, cancer vaccines will first be used therapeutically, to boost the immune response to cancer in patients already afflicted. A vaccine that would actually prevent cancer in high-risk individuals will be the next step, although this is probably years away. **NEW MEDICINE** has just released a cancer vaccine report providing an in-depth analysis of the cancer vaccine sector (see page 5). This report provides a comprehensive analysis of the cancer vaccine sector in terms of: **basic science** (tumorigenesis, oncogenes, tumor-suppressor genes, mitogenic growth factors and growth inhibitory factors, viral causes, apoptosis, immune response, tumor antigens, immune surveillance); **technology** (antiviral vaccines against cancer, nonspecific and specific active immunotherapy, whole tumor cell vaccines, gene transfer, protein antigens, adoptive immunotherapy, activated killer cells, tumor-infiltrating lymphocytes, passive immunotherapy, adjuvants); **indications and epidemiology** (worldwide incidence by disease severity and survival and mortality statistics for major cancers); **products under development** (a comprehensive database of over 160 cancer vaccines in development worldwide, including data on developer/affiliate, technology and clinical status); **market opportunities worldwide** (by indication based on candidate populations and suggested treatment costs); and **developer profiles** (over 60 companies).

NEW
MEDICINE | **Oncology
KnowledgeBASE™**

NEW MEDICINE, the publisher of FUTURE ONCOLOGY, the premier analytical newsletter in the oncology field has released a comprehensive resource, **Oncology KnowledgeBASE**, to keep its clients informed of developments in the cancer field.

nm|OK is a resource developed for the executive/professional working in the oncology field. This is not another piece of the puzzle but a comprehensive all-in-one listing of everything you wanted to know about this field, updated daily. nm|OK was designed to reside in one's computer at one's desk and allow immediate and convenient access to information in this field. For instance, when a competitor releases clinical results of a novel agent in development, the nm|OK subscriber can instantaneously compare these results with those of other agents in development for the same or a related indication. When a new affiliation/collaboration is announced between two companies or a licensing agreement with an academic institution, nm|OK lets one review all other affiliations/collaborations of the key players.

The oncology field is advancing at a breakneck pace with new developments in basic science, progress in preclinical research, and results of clinical evaluations being reported on a daily basis and new drugs being approved for indications for which no new drugs had been introduced for decades. History will view the 1990s as pivotal years in the war against cancer but there is still a long way to go before a cure is found.

nm|OK was designed to be used by executives who need to follow closely any developments in this area, in terms of:

- product development status
- competitive pipelines
- affiliations
- novel drug development opportunities
- clinical development status
- current worldwide epidemiology
- current worldwide sales of commercially available agents
- market opportunities of agents in development

nm|OK consists of a number of modules (New Drugs, Marketed Drugs, Companies, Diagnostics, Devices, Epidemiology, Markets, Indications, Technologies, Mechanisms, Drug Delivery, Markers, etc.) covering every important aspect of the cancer field.

The currently available module, New Drugs, incorporate over 950 records of agents in development for cancer and complications associated with the disease and its treatment (anemia, cachexia, edema, emesis, hypercalcemia, infection,

mucositis, neutropenia, pain, thrombocytopenia, xerostomia, etc.). Each record contains information on every aspect of the agent in development. For instance, do you need to know:

How many drugs are in development based on the mechanism of angiogenesis? (about 40)

Who is the developer?

Is there a collaboration and with whom?

What is the status of the drug?

How is it administered? etc.

How many drugs are in development for prostate cancer? (140)

How many are in phase III? (21)

How many of these are oral agents? (7)

What are the results of clinical trials? etc.

How many drugs are there in the Pharmacia & Upjohn pipeline? (8) and those of its affiliates? (5)

What is the status of these drugs?

Which companies have forged alliances with Bristol-Myers Squibb? [Chiroscience Group, EntreMed, Pharma Mar, Progenics Pharmaceuticals, Somatix Therapy (Cell Genesys), etc.]; for what products/enabling technologies?

How many drugs in development are orally bioavailable? (73)

How many of these are in clinical trials? (51)

How many drugs are in preclinical trials? (257); in research? (121); in phase I? (260)

How many drugs have been discontinued in the last several years? (18); how many of these were in phase III clinical trials? (6)

Why were they discontinued?

How many affiliations have been concluded by M. D. Anderson Cancer Center? (14)

nm|OK

**A UNIQUE ELECTRONIC RESOURCE
IN THE CANCER FIELD.**

